The Procedureless Elipse Gastric Balloon Program: Multicenter Experience in 1770 Consecutive Patients

Show simple item record Ienca, R. Al Jarallah, Mohammed Caballero, Adelardo Giardiello, Cristiano Rosa, Michele Kolmer, Sébastien Sebbag, Hugues Hansoulle, Julie Quartararo, Giovanni Al Samman Zouaghi, Sophie Juneja, Girish Murcia, Sébastien Turro, Roman Pagan, Alberto Badiuddin, Faruq Dargent, Jérôme Urbain, Pierre Paveliu, Stefan Schiano di Cola, Rita Selvaggio, Corrado Al Kuwari, Mohammed 2021-05-13T06:50:21Z
dc.description.abstract [eng] Purpose The Elipse balloon is a novel, non-endoscopic option for weight loss. It is swallowed and filled with fluid. After 4 months, the balloon self-empties and is excreted naturally. Aim of the study was to evaluate safety and efficacy of Elipse balloon in a large, multicenter, population. Materials and Methods Data from 1770 consecutive Elipse balloon patients was analyzed. Data included weight loss, metabolic parameters, ease of placement, device performance, and complications. Results Baseline patient characteristics were mean age 38.8 ± 12, mean weight 94.6 ± 18.9 kg, and mean BMI 34.4 ± 5.3 kg/m2. Triglycerides were 145.1 ± 62.8 mg/dL, LDL cholesterol was 133.1 ± 48.1 mg/dL, and HbA1c was 5.1 ± 1.1%. Four-month results were WL 13.5 ± 5.8 kg, %EWL 67.0 ± 64.1, BMI reduction 4.9 ± 2.0, and %TBWL 14.2 ± 5.0. All metabolic parameters improved. 99.9% of patients were able to swallow the device with 35.9% requiring stylet assistance. Eleven (0.6%) empty balloons were vomited after residence. Fifty-two (2.9%) patients had intolerance requiring balloon removal. Eleven (0.6%) balloons deflated early. There were three small bowel obstructions requiring laparoscopic surgery. All three occurred in 2016 from an earlier design of the balloon. Four (0.02%) spontaneous hyperinflations occurred. There was one (0.06%) case each of esophagitis, pancreatitis, gastric dilation, gastric outlet obstruction, delayed intestinal balloon transit, and gastric perforation (repaired laparoscopically). Conclusion The ElipseTM Balloon demonstrated an excellent safety profile. The balloon also exhibited remarkable efficacy with 14.2% TBWL and improvement across all metabolic parameters.
dc.format application/pdf
dc.relation.isformatof Versió postprint del document publicat a:
dc.relation.ispartof Obesity Surgery, 2020, vol. 30, p. 3354-3362
dc.subject.classification 617 - Cirurgia. Ortopèdia. Oftalmologia
dc.subject.other 617 - Surgery. Orthopaedics. Ophthalmology
dc.title The Procedureless Elipse Gastric Balloon Program: Multicenter Experience in 1770 Consecutive Patients
dc.type info:eu-repo/semantics/article
dc.type info:eu-repo/semantics/acceptedVersion 2021-05-13T06:50:22Z info:eu-repo/date/embargoEnd/2026-12-31
dc.embargo 2026-12-31
dc.rights.accessRights info:eu-repo/semantics/embargoedAccess

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search Repository

Advanced Search


My Account